Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trigen has initiated a phase I clinical study with its lesion-specific platelet adhesion inhibitor, PR-15, following strong efficacy displayed in preclinical models.
Subscribe to our email newsletter
PR-15 is being evaluated in a phase I single dose study which aims to define the safety, tolerability and PK/PD profile of the drug candidate. PR-15 is being developed to treat acute arterial thrombosis and prevent progression of atherosclerosis following an acute event.
PR-15 is a soluble form of the GPVI receptor on blood platelets. As such, it binds selectively to collagen exposed in ruptured atherosclerotic plaques where it prevents GPVI-mediated platelet adhesion and activation. Such activation normally triggers heart attacks and stroke.
PR-15 is a lesion-specific anti-thrombotic since it prevents the binding of platelet-bound GPVI to collagen exposed in ruptured atherosclerotic plaques but not elsewhere in the vasculature. Trigen believes this feature gives PR-15 the potential for significant clinical benefit with less bleeding risk as compared to traditional anti-platelet agents as it will not affect normal platelet function, leaving hemostasis undisturbed.
“PR-15’s mode of action has been likened to that of an internal ‘sticking plaster’, coating the damaged vessel wall and so enabling repair. Naturally, we are very keen to evaluate and demonstrate the clinical utility of this drug,” said Dr Sophie Combe, vice president of Clinical Development at Trigen.